• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home The Classics Hematology/Oncology Classics

Stereotactic body radiotherapy as a state of the art treatment option in inoperable non-small cell lung cancer [Classics Series]

byDeepti Shroff Karhade
July 2, 2022
in Hematology/Oncology Classics, The Classics
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

This study summary is an excerpt from the book 2 Minute Medicine’s The Classics in Medicine: Summaries of the Landmark Trials

1. Stereotactic body radiotherapy (SBRT) achieved a 3 year local tumor control rate of 92% with limited toxicity, making SBRT a valuable treatment option in inoperable (and potentially even operable) patients

Original Date of Publication: July 2009

Study Rundown: Lung cancer is the most common cancer worldwide, and non-small cell lung cancer (NSCLC) accounts for the majority of cases. Surgical resection remains the mainstay of treatment for patients with stage I NSCLC approved for surgery. Historically, medically inoperable patients with NSCLC were managed with radiation therapy (RT) and showed poor five-year survival rates, presumably from insufficient doses. Phase II trials, however, have shown that SBRT – a method using precise targeted radiation to minimize radiation to adjacent tissue – produces tumor control rates even higher than surgical intervention. SBRT can thus administer biologic doses up to twice as high as RT without harmful affects to normal tissue. Though studies have shown good rates of local tumor control and toxicity for SBRT, the vast majority have been retrospective. Given the paucity of prospective trials and the lack of long-term follow-up data, application of SBRT remains limited.  This multicenter prospective phase II study assessed the 36 month survival of NSCLC and evaluated tumor control, survival, and toxicity based on SBRT. The results indicate a tumor control rate similar to surgery in operative cases, a favorable 3 year cancer specific-survival rate, and minimal toxicity. The later Radiation Therapy Oncology Group (RTOG) 0236 trial from Timmerman et al. reported an even high rate of primary tumor control with minimal toxicity. It is noted that the optimal dose and schedule for SBRT is still undefined for treating NSCLC.

Click to read the study in the Journal of Clinical Oncology

In-Depth [prospective cohort]: This prospective phase II study recruited 60 patients with medically inoperable stage I NSCLC, mainly due to COPD (60%) or cardiovascular disease (25%) across 7 centers in Nordic countries. Patients with prior malignancy or a primary tumor next to the trachea, main bronchus, or esophagus were excluded to ensure safety. After patients were referred to RT units, two were excluded based on insufficient radiation dose and one was lost to follow-up. The remaining 57 patients with NSCLC (70% T1N0M0 and 30% T2N0M0) were treated with SBRT using 6 MV from a linear accelerator, after defining the gross tumor volume (GTV, the size of the macroscopic tumor), clinical target volume (CTV, the volume of microscopic and gross malignant tissue), and planning target volume (PTV, the CTV plus a margin of safety around the tumor). CT was performed before each treatment to verify target reproducibility. Patients were then assessed with toxicity grading and chest CT or x-ray at 6 weeks, every 3 months for the first 18 months, and at 24 and 36 months following treatment. Lung function was measured at 3, 9, and 18 months using the Karnofsky performance score. After the study’s conclusion at 36 months, the Kaplan-Meier estimated progression-free survival rate was 52%. The lung cancer-specific survival rates at 1, 2, and 3 years were 93%, 88%, and 88%, respectively. The Kaplan-Meier estimated local tumor control at 3 years was 92%. Four patients (7%), all with T2N0M0 tumors, showed local tumor progression. No patient was lethally affected by SBRT and 14 patients (25%) had no pulmonary adverse effects.

RELATED REPORTS

Ivonescimab improves survival in advanced non-small cell lung cancer

Pembrolizumab with radiotherapy and surgery improves survival in high-risk soft tissue sarcoma

Radiotherapy and abiraterone improve survival in low-volume metastatic castration-sensitive prostate cancer

Baumann P, Nyman J, Hoyer M, Wennberg B, Gagliardi G, Lax I, et al. Outcome in a Prospective Phase II Trial of Medically Inoperable Stage I Non–Small-Cell Lung Cancer Patients Treated With Stereotactic Body Radiotherapy. JCO. 2009 Jul 10;27(20):3290–6.

Additional Review:

Timmerman R, Paulus R, Galvin J, Michalski J, Straube W, Bradley J, et al. Stereotactic Body Radiation Therapy for Inoperable Early Stage Lung Cancer. JAMA. 2010 Mar 17;303(11):1070–6.

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: cancer survivalnon-small cell lung cancer (NSCLC)radiotherapytumor control
Previous Post

Health system-based care associated with better treatment use and high rates of tobacco abstinence at 3 months post-discharge in hospitalized smokers

Next Post

2 Minute Medicine Rewind July 4, 2022

RelatedReports

Lessons from real-world implementation of lung cancer screening
Chronic Disease

Ivonescimab improves survival in advanced non-small cell lung cancer

April 30, 2025
Increased frailty associated with childhood cancer survivorship
Chronic Disease

Pembrolizumab with radiotherapy and surgery improves survival in high-risk soft tissue sarcoma

December 19, 2024
Androgen deprivation in prostate cancer: intermittent may compromise survival
Chronic Disease

Radiotherapy and abiraterone improve survival in low-volume metastatic castration-sensitive prostate cancer

December 18, 2024
Cervical cancer screening practices less cost-effective than suggested guidelines
Chronic Disease

Induction chemotherapy followed by chemoradiotherapy improves survival in advanced cervical cancer

November 1, 2024
Next Post
Patients with low back pain or pain at multiple sites at highest risk for chronic opioid use

2 Minute Medicine Rewind July 4, 2022

Quick Take: Intravenous patient-controlled analgesia versus thoracic epidural analgesia after open liver surgery

Early initiation of poststernotomy cardiac rehabilitation exercise training is effective and safe

FOLFOX combined with nivolumab and trastuzumab in ERBB2-positive esophagogastric adenocarcinoma is an emerging therapy option

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Time-restricted eating does not confer changes in sleep, mood, or quality of life
  • Commonly cited medication triggers may not increase risk of microscopic colitis among older adults
  • Ablation may reduce stroke risk, death, heart failure hospitalization in patients with atrial fibrillation
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.